Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2019

01-12-2019 | Anal Cancer | ASO Author Reflections

ASO Author Reflections: Optimal Management of Anal Adenocarcinoma: Clues from a Large, National Database

Authors: Gary D. Lewis, MD, Bin S. Teh, MD

Published in: Annals of Surgical Oncology | Special Issue 3/2019

Login to get access

Excerpt

Adenocarcinoma of the anus is a rare subtype of anal cancer and is thought to represent between 5 and 10% of all anal cancer cases.1 Previous studies have reported that anal adenocarcinoma (AA) carries a worse prognosis when compared with anal squamous cell carcinoma (AS).1,2 However, due to the rarity of this disease, there are currently no evidence-based treatment guidelines. AS is treated with definitive chemoradiation (CRT). In contrast, AA has typically been treated similarly to a low-lying rectal adenocarcinoma, i.e. trimodality therapy with neoadjuvant CRT followed by abdominoperineal resection (APR). Unfortunately, the data on this treatment strategy are limited to retrospective institutional reviews. …
Literature
1.
Franklin RA, Giri S, Valasareddy P, Lands LT, Martin MG. Comparative survival of patients with anal adenocarcinoma, squamous cell carcinoma of the anus, and rectal adenocarcinoma. Clin Colorectal Cancer. 2016;15(1):47–53.CrossRef
2.
Anwar S, Welbourn H, Hill J, Sebag-Montefiore D. Adenocarcinoma of the anal canal: a systematic review. Colorectal Dis. 2013;15(12):1481–1488.CrossRef
3.
Lewis GD, Haque W, Butler EB, et al. Survival outcomes and patterns of management for anal adenocarcinoma. Ann Surg Oncol. 2019;26:1351–1357.CrossRef
Metadata
Title
ASO Author Reflections: Optimal Management of Anal Adenocarcinoma: Clues from a Large, National Database
Authors
Gary D. Lewis, MD
Bin S. Teh, MD
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07466-w

Other articles of this Special Issue 3/2019

Annals of Surgical Oncology 3/2019 Go to the issue

ASO Author Reflections

ASO Author Reflections: The Role of Postoperative Adjuvant Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma and Hepatic Vein Invasion

ASO Author Reflections

ASO Author Reflections: Induction Systemic Chemotherapy for Peritoneal Metastasis of Gastric Cancer

ASO Author Reflections

ASO Author Reflections: Clarifying the Controversy Generated by Non-inferiority Trials of Laparoscopic Surgery for Rectal Cancer

ASO Author Reflections

ASO Author Reflections: Homeobox C10 Influences on the Malignant Phenotype of Gastric Cancer Cell Lines and its Elevated Expression Positively Correlates with Recurrence and Poor Survival

ASO Author Reflections

ASO Author Reflections: Breast Contour-Preserving Procedures as a Means to Address the Esthetic Outcome of Breast Cancer Treatment

ASO Author Reflections

ASO Author Reflections: Increased Expression of DNAJC12 is Associated with Aggressive Phenotype of Gastric Cancer